🏛️ Company factsSEC filings + FINRA official data
Annual revenue $1.9B · latest quarter up 2.1% YoY · not yet profitable (FY net loss $2.8B) · short activity within its normal range.
FY revenue
$1.9B
2025-12
Latest Q YoY
+2.1%
FY net loss
$2.8B
Diluted EPS
$-7.26
Short volume
61.1%
20d avg 58.2% · normal
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-08-12passive (13G)Capital World Investors
- 2026-08-06passive (13G)FMR LLC
- 2026-07-24passive (13G)BAILLIE GIFFORD & CO
- 2026-04-30passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-27passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability Low · 35/100Nasdaq analyst consensus · the pre-news baseline
There is no clear consensus on this stock (thin coverage or wide disagreement) — 'beating expectations' means little here.
- Jun 2026-$1.97 vs -$1.970%
- Mar 2026-$1.18 vs -$3.02+60.93%
- Dec 2025-$2.11 vs -$2.60+18.85%
- Sep 2025-$0.51 vs -$2.15+76.28%
Analyst estimates, not our forecast · not investment advice
🧭 +5.4% today with no fresh news · why?
- 📊 Market+1.6%S&P +0.9% × beta 1.9
- 💸 Money flowMFI 45 · net outflow · volume 0.5× average
- 🔀 PeersBNTX +0.3%MRK -0.5%LLY -0.7%PFE +0.3%NVAX +1.3%Peers are mixed today — this move looks more stock-specific.
- 🕰️ Old news, still digesting▲ Merck, Moderna Cancer Vaccine Breakthrough Couldstructural impact active, ~36 days left
- 🕰️ Old news, still digesting▲ Investors Should Position For Humanoid Robot Boostructural impact active, ~36 days left
- ❓ Remainder~+3.8% has no clear driver = market noise. Moves without reasons are normal — don't force a story.
Educational decomposition · not investment advice
What's moving this stock lately
2 direct · 0 2nd-order · 0 thematicRanked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)
The Merck-partnered individualized neoantigen therapy is Moderna's key non-COVID growth story; heightened media attention raises focus on a potential 2027 approval
Also named: BNTX · MRK · PSNL · ADPT · ILMN · TMO
The mRNA-plus-AI platform narrative is reiterated, helping sustain investor focus on the valuation of its technology platform.
Also named: CBRS · CRWD · NET · NVDA · PANW · MRK
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
17 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →